From 2015 to 2017, Wuhan Xinxing Jingying Pharmaceuticals, LLC ("Xinxing Pharmaceuticals") monopolized methyl salicylate active pharmaceutical ingredients (APIs) market of China through multiple contractual arrangements. In January 2017, Xinxing Pharmaceuticals was fined RMB2.2 million by the former Administration for Industry and Commerce of Hubei Province (a former AMEA of Hubei Province, China) for abusing its market dominance to sell drugs at excessive prices and attached unreasonable transaction conditions to its traders. Case Brief: In 2014, Xinxing Pharmaceuticals entered into exclusive sales agreements, in the name of Wuhan HH Pharmaceuticals Co., Ltd. and Hainan HF Pharmaceuticals Co., Ltd. (collectively, “Exclusive Agents”), with Guangdong Foshan Nanhai Zhongnan Pharma
Share on
|
|
The Chinese Administration for Industry and Commerce of Hubei Province decides that a company attained market dominance through multiple contractual arrangements (Xinxing Jingying Pharmaceuticals)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
